Gedeon Richter
To see an up-to date selection of historical analyses and insights on
Gedeon Richter,
visit our
new, dynamically updated Company Summary report pages for Gedeon Richter.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Gedeon Richter are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Gedeon Richter,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Gedeon Richter |
1 |
Ednyt |
enalapril |
ACE inhibitor |
89 |
95 |
|
6% |
|
|
|
2 |
Cavinton |
vinpocetine |
Oxygen enhancer |
98 |
86 |
|
(13%) |
|
|
|
3 |
Quamatel |
famotidine |
H2 antagonist |
47 |
44 |
|
(6%) |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Gedeon Richter |
- |
RGH-188 |
Central Nervous System |
Anti-psychotics |
Dopamine D1 & D2 antagonist |
Phase II |
|
|
- |
RGH-896 |
Central Nervous System |
Non-narcotic analgesics |
NMDA 2B receptor antagonist |
Phase II |
|
|
- |
mGLUR1/5 Antagonist |
Central Nervous System |
Other CNS drugs |
Metabotropic glutamate receptor 1/5 (mGluR1/5) antagonist |
Pre-clinical |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Gedeon Richter |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
| Market Capitalisation |
2,701 |
2,701 |
| PE Ratio (diluted) - Normalised (x) |
11.9 |
11.1 |
|
|
| Valuing the Enterprise |
| Enterprise Value |
2,435 |
2,435 |
| Free Cash Flow (Pre-Dividends) |
67 |
108 |
| FCF Yield (%) |
2.8% |
4.4% |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
866 |
997 |
| Cost of Goods Sold |
(379) |
(427) |
| S,G & A |
(219) |
(253) |
| R&D |
(63) |
(69) |
| Other Income/ Expense - Net |
(6) |
(12) |
| Associate/ Equity Affiliate Income |
5 |
5 |
| EBIT - Normalised |
203 |
241 |
| Net Interest & Financial Items |
29 |
8 |
| Pre-tax Profits - Normalised |
232 |
248 |
| Income Before Taxes |
232 |
248 |
| Tax |
(3) |
(3) |
| Tax Rate (%) |
1.2% |
1.4% |
| Minorities |
(2) |
(1) |
| Net Income - Reported |
227 |
244 |
| Net Income - Normalised |
227 |
244 |
|
|
| Per Share Data |
| EPS - Diluted |
12.20 |
13.10 |
| EPS - Basic |
12.22 |
13.11 |
| EPS - Normalised (diluted) |
12.20 |
13.10 |
| EPS - Normalised (basic) |
12.22 |
13.11 |
| Avg. Shares Outstanding - Diluted |
18.6 |
18.6 |
| Avg. Shares Outstanding - Basic |
18.6 |
18.6 |
| DPS |
2.82 |
3.59 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
|
(Forest Laboratories)
|
30-Sep-2008 |
| Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
|
(Gedeon Richter)
|
30-Sep-2008 |
| New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
|
(Biogen Idec)
|
18-Sep-2008 |
| Positive CHMP Opinion for Abstral (Rapinyl)
|
(ProStrakan)
|
27-Jun-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Gedeon Richter |
Abstral |
fentanyl |
|
|
Aflamin |
aceclofenac |
|
|
Aktil |
amoxicillin & clavulanate |
|
|
Allyloestrenol |
allylestrenol |
|
|
Andante |
zaleplon |
|
|
Anteovin |
ethinyl estradiol & levonorgestrel |
|
|
Arduan |
pipecuronium bromide |
|
|
Atorvox |
atorvastatin |
|
|
Avonex |
interferon beta-1a |
|
|
Calcisedron-D |
alendronate, calcium & vitamin D |
|
|
Calumid |
bicalutamide |
|
|
Cavinton |
vinpocetine |
|
|
Centrum |
multivitamin |
|
|
Clindesse |
clindamycin |
|
|
Curiosin |
zinc hyaluronate |
|
|
Deprexin |
fluoxetine |
|
|
Doxium |
calcium dobesilate |
|
|
Drospirenone & Ethinyl estradiol |
drospirenone & ethinyl estradiol |
|
|
Ednyt |
enalapril |
|
|
Ednyt HCT |
enalapril & hydrochlorothiazide |
|
|
Efectin |
venlafaxine |
|
|
Emetron |
ondansetron |
|
|
Ergot alkaloids |
bromocriptine |
|
|
Escapelle |
levonorgestrel |
|
|
Estrimax |
estradiol |
|
|
Fem7 |
estradiol |
|
|
Fem7 Combi Patch |
estradiol hemihydrate & levonorgestrel |
|
|
Fem7 Plus |
estradiol & levonorgestrel |
|
|
Fortofan |
formoterol |
|
|
Glindia |
glimepiride |
|
|
Gordius |
gabapentin |
|
|
Gordox |
aprotinin (bovine) |
|
|
Gynazole-1 |
butoconazole |
|
|
Haloperidol |
haloperidol |
|
|
Histodil |
cimetidine |
|
|
Hunperdal |
risperidone |
|
|
Hyron |
terazosin |
|
|
Klion |
metronidazole |
|
|
Lamolep |
lamotrigine |
|
|
Lansone |
lansoprazole |
|
|
Levonelle-2 |
levonorgestrel |
|
|
Lindynette |
gestodene |
|
|
Lipidil/ Lipanthyl |
fenofibrate |
|
|
Lisonorm |
lisinopril & amlodipine |
|
|
Lisopress |
lisinopril |
|
|
mGLUR1/5 Antagonist |
- |
|
|
Milligest |
ethinyl estradiol & gestodene |
|
|
Mycosyst |
fluconazole |
|
|
Mydeton |
tolperisone |
|
|
Nandrolon |
nandrolone |
|
|
Normodipine |
amlodipine besylate |
|
|
Novynett |
desogestrel & ethinyl estradiol |
|
|
Nurofen |
ibuprofen |
|
|
Ovidon |
ethinyl estradiol & levonorgestrel |
|
|
Panangin |
magnesium aspartate & potassium aspartate |
|
|
Phenylbutazone |
phenylbutazone |
|
|
Portiron |
losartan |
|
|
Prednisolon |
prednisolone |
|
|
Prosterid |
finasteride |
|
|
Quamatel |
famotidine |
|
|
Regulon |
desogestrel & ethinyl estradiol |
|
|
Rexetin |
paroxetine |
|
|
RGH-188 |
cariprazine |
|
|
RGH-363 |
- |
|
|
RGH-512 |
- |
|
|
RGH-790 |
- |
|
|
RGH-896 |
radiprodil |
|
|
Rigevidon |
ethinyl estradiol & levonorgestrel |
|
|
Sedron |
alendronate |
|
|
Silperisone |
silperisone |
|
|
Stugeron |
cinnarizine |
|
|
Suprax |
cefixime |
|
|
Tamsol |
tamsulosin |
|
|
Tardyferon |
ferrous sulfate |
|
|
Tarivid Trio |
ofloxacin |
|
|
Terbisil |
terbinafine |
|
|
Triaklim |
estradiol & norethindrone acetate |
|
|
Tri-Regol |
estradiol & levonorgestrel |
|
|
Tulita |
estradiol & norethisterone |
|
|
Uro-Vaxom |
escherichia coli vaccine |
|
|
Verospiron |
spironolactone |
|
|
Vinblastine |
vinblastine |
|
|
Vincristine |
vincristine |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
